SOURCE: Cell Bio-Systems

October 25, 2005 13:18 ET

New Production Accessory Will Be Added Ahead of Schedule

SAN DIEGO, CA -- (MARKET WIRE) -- October 25, 2005 -- Cell Bio-Systems, Inc. (OTC: CBSI) announced today that its first accessory product, The Superluer Transfer, has moved ahead of schedule. The Superluer Transfer is a device typically used by surgeons to transfer tissue such as adipose taken during a harvesting procedure to an injection cannula.

According to Marc Pilkington, CEO, "We plan to sell these transfer instruments under the Tulip Disposable Products, along with our new line of disposable cannulas. This is an important accessory, and is now planned to be delivered in the first quarter of 2006."

In addition to the new transfer instrument, Pilkington also said that CBSI will likely introduce two additional tip styles ahead of schedule in Q1 2006.

Darin Andersen, President & COO, explained that the patented Superluer Transfer is a key complementary accessory that allows the safe transfer of tissue between luer syringes. "Transferring tissue between syringes is a procedure done in plastic surgery as well as other medical procedure segments," said Andersen. "Our patented connection system, along with the disposability of this product, will potentially make this a safer procedure for the surgical team and the patient alike." Andersen also commented that "The Superluer Transfer along with the additional tip styles may allow for revenues to potentially ramp up at a higher rate than originally planned."

About Cell Bio-Systems, Inc.

Cell Bio-Systems, Inc. (CBSI) is a Nevada corporation whose operations are based in San Diego, California. Founded in 2004, Cell Bio-Systems is a Medical Device, Biotechnology Company seeking to manufacture and distribute patented technologies for the Plastic & Cosmetic Surgery, Biopsy, Orthopedic Surgery, Stem Cell Therapy and other Living Tissue markets. Cell Bio-System is the exclusive licensee of patented syringe connection devices which use the worldwide recognized Tulip brand name. Cell Bio-Systems will manufacture, market, and distribute medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets.

This press release contains certain forward-looking information about Cell Bio-Systems, Inc. ("Cell Bio-Systems") which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Cell Bio-Systems, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy, the grade and quantity of minerals in our projects may not be economic, we do not have fee title to our properties, but derive our right through leases and the Mining Law, we are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission, we trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Cell Bio-Systems does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:

    Investor Relations
    Bill Hales
    858-244-4800